Chong Kun Dang Bio Collaborates with Yonsei University to Develop Microbiome Therapeutics

On the 20th, Severance Hospital held an opening ceremony for the Microbiome Joint Research Center ‘CYMRC’. Kim Young-joo, CEO of Chong Kun Dang; Lee Eun-jik, Dean of Yonsei University College of Medicine; Lee Jung-jin, CEO of Chong Kun Dang Bio; Yoon Dong-seop, Director of Yonsei Medical Center; Kim Tae-young, CEO of Chong Kun Dang Holdings; Ha Jong-won, Director of Severance Hospital; and Kim Chang-hoon, Director of the Human Microbiome Center (from left) participated in the ribbon-cutting ceremony and took a commemorative photo. (Photo by Chong Kun Dang Bio)

[Asia Economy Reporter Chunhee Lee] Chong Kun Dang Bio is launching a microbiome research center in collaboration with Yonsei Medical Center to develop therapeutics utilizing gut microorganisms.

On the 20th, Chong Kun Dang Bio announced on the 23rd that it held an opening ceremony for the microbiome joint research center, ‘CYMRC (CKDBio-YONSEI Microbiome Research Center),’ at Severance Hospital in Seodaemun-gu, Seoul.

The opening ceremony was attended by key figures from both sides, including Yoon Dong-seop, President of Yonsei Medical Center, Lee Eun-jik, Dean of Yonsei University College of Medicine, Kim Tae-young, CEO of Chong Kun Dang Holdings, and Lee Jeong-jin, CEO of Chong Kun Dang Bio.

Through the newly opened CYMRC, Chong Kun Dang Bio plans to establish research and development infrastructure and a medical consortium to strengthen its microbiome drug pipeline targeting indications with high unmet needs such as inflammatory bowel disease (IBD), Alzheimer’s dementia, and liver diseases. The research center is equipped with state-of-the-art facilities, including automated analyzers and next-generation sequencing (NGS) devices, capable of deriving and evaluating human-derived microbiome-based candidate substances.

A representative from Chong Kun Dang Bio stated, “Recently, microbiome therapeutic development has been actively progressing domestically and internationally, focusing on metabolic and neurological diseases,” adding, “Through CYMRC, we will accelerate the development of first-in-class and best-in-class microbiome therapeutics within our portfolio.”